Share This Article:

Immunovirologic Evaluation of Triomune (Lamivudine, Stavudine and Nevirapine) Antiretroviral Therapy in First Line HIV-1 Adult Patients in N’Djamena, Chad

Abstract Full-Text HTML Download Download as PDF (Size:2517KB) PP. 301-305
DOI: 10.4236/wja.2014.43035    2,678 Downloads   3,106 Views   Citations


Contexte: The fight against HIV/AIDS epidemics is one of the greatest challenges of this century. The epidemic affects generally under-developed countries, and Sub-Saharan Africa are the most concerned. The combined marketed form known as Triomune was used as first-line treatment in several sub-Saharan African Countries (60% of VIH infected people), including Chad. However, no evaluation has been done for that treatment in the country. Objective: To evaluate the efficacy and safety immuno-virological of Triomune at the General Hospital in N’Djamena/Chad. Methods: 48 HIV-1 positive patients eligible for ARV treatment were enrolled in our study, and they have been then followed for 8 months. We have measured in these patients the CD4 cell count before treatment and at the 8th month of treatment. After 8 months of treatment, we have also evaluated the Lymphocyte T CD4 and the plasma viral load (VL). Comparisons of means of CD4 lymphocytes and plasma CV (≥1000 copies/ml) were used to define treatment failure. Results: 48 patients were under Triomune regime. The average CD4 count was decreased from 462 ± 179.22 [56 - 981] cells/mm3 before treatment to 327.23 ± 153.77 [10 - 1008] cells/mm3 at the 8th month of treatment. The mean plasma viral load for patients was 66008.62 copies/ml. The failure rate to Triomune was 43.75% (21/48). Conclusion: Aside from the side effects already described for Triomune, our study reveals a high treatment failure rate. Hence, there is the need of regular revisions of therapeutic regime administer in the first intention.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Adawaye, C. , Erick, K. , Djibrine, S. , Chahad, A. , Moussa, A. , Bertin, T. , Dolores, V. and Michel, M. (2014) Immunovirologic Evaluation of Triomune (Lamivudine, Stavudine and Nevirapine) Antiretroviral Therapy in First Line HIV-1 Adult Patients in N’Djamena, Chad. World Journal of AIDS, 4, 301-305. doi: 10.4236/wja.2014.43035.


[1] ONUSIDA, Rapport Mondial (2012) Rapport ONUSIDA sur l’épidémie mondiale de sida. JC2417 Fconsulté en Novembre 2012.
[2] Bandoumal, O., Kostelngar, N., Tchobkreo, B., Madnodji, R., et al. (2005) Enquête Nationale de prévalence de l’infection à VIH au Tchad. Institut National de la Statistique, des Etudes Economiques et Démographiques, INSEED, 2005.
[3] Lihana, R.W., Ssemwanga, D., Abimikua, A. and Ndembi, N. (2012) Update on HIV-1 Diversity in Africa: A Decade in Review. AIDS Reviews, 14, 83-100.
[4] Vidal, N., Koyalta, D., Richard, V., Lechiche, C., Ndinaromtan, T., Djimasngar, A., Delaporte, E. and Peeters, M. (2003) High Genetic Diversity of HIV-1 Strains in Chad, West Central Africa. Journal of Acquired Immune Deficiency Syndromes, 33, 239-246.
[5] Hamers, R.L., Derdelinckx, I., van Vugt, M., Stevens, W., Rinke de Wit, T.F. and Schuurman, R. (2008).The Status of HIV-1 Resistance to Antiretroviral Drugs in Sub-Saharan Africa. Antiviral Therapy, 13, 625-639.
[6] Koyalta, D., Charpentier, C., Beassamda, J., Rey, E., Si-Mohamed, A., Djemadji-Oudjeil, N. and Belec, L. (2009) High Frequency of Antiretroviral Drug Resistance among HIV-Infected Adults Receiving First-Line Highly Active Antiretroviral Therapy in N’Djamena, Chad. Clinical Infectious Diseases, 49, 155-159.
[7] Garcia, M.V., Mukeba-Tshialala, D., Vaira, D. and Moutschen, M. (2009).Triomune: La Thérapie du pauvre? Revue Médicale de Liège, 64, 30-44.
[8] Integrated Regional Information Networks (IRIN), AFRIQUE (2010) L’échec thérapeutique trop souvent mal détecté. consulté de Novembre 2012.
[9] WHO (2006) Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Recommendations for a Public Health Approach. Revisions. 2006. Consulté en Novembre 2012.
[10] Ministère de la santé publique. Programme national de lutte contre le Sida (2006) Guide national de prise en charge de l’infection par le VIH. Ministère de la Santé Publique/Programme National de Lutte contre le Sida (PNLS).
[11] Lowe, S.H., Hassink, E.A., Van Eck-Smit, B.L., Borleffs, J.C., Lange, J.M. and Reiss, P. (2007) Stavudine but Not Didanosine as Part of HAARR Contributes to Péripherallipoatrophy: A Substudy from Antiretroviral Regimen Evaluation Study (ARES). HIV Clinical Trials, 8, 337-344.
[12] Tapsfield, J., Mathews, T., Lungu, M. and van Oosterhout, JJ. (2011) Underreporting of Side Effects of Standard First-Line ART in the Routine Setting in Blantyre, Malawi. Malawi Medical Journal, 23, 115-117.
[13] Organisation Mondiale de la Santé (2009) Recommandations rapides pour la prise en charge de l’infection par le VIH de l’adulte et de l’adolescent dans les pays à ressources limitées. OMS, Genève.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.